

# Tony Mok

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6343815/tony-mok-publications-by-year.pdf>  
**Version:** 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

467 papers	55,350 citations	97 h-index	231 g-index
568 ext. papers	66,536 ext. citations	6.1 avg, IF	7.32 L-index

#	Paper	IF	Citations
467	Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , JCO2101845	2.2	9
466	Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non-Small-Cell Lung Cancer.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , JCO2102010	2.2	4
465	In Response to Outcomes by ALK Status (Immunohistochemistry or Fluorescence In Situ Hybridization) in ALEX. <i>Journal of Thoracic Oncology</i> , <b>2022</b> , 17, e62-e63	8.9	
464	Three-year follow-up and patient-reported outcomes from CheckMate 078: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer.. <i>Lung Cancer</i> , <b>2021</b> , 165, 71-81	5.9	0
463	363 KEYNOTE-042 5-year survival update: pembrolizumab versus chemotherapy in patients with previously untreated, PD-L1 $\beta$ positive, locally advanced or metastatic non-small-cell lung cancer <b>2021</b> , 9, A390-A390		0
462	Incorporating circulating tumor DNA detection to radiographic assessment for treatment response in advanced EGFR-mutant lung cancer. <i>Lung Cancer</i> , <b>2021</b> , 163, 14-18	5.9	0
461	364 KRAS mutations in patients with nonsquamous non-small-cell lung cancer: prevalence and relationship with PD-L1 expression, tumor mutation burden and smoking status <b>2021</b> , 9, A391-A391		
460	IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain. <i>Journal of Thoracic Oncology</i> , <b>2021</b> ,	8.9	17
459	Dacomitinib as first-line treatment for EGFR mutation-positive non-small cell lung cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , <b>2021</b> , 6, 161-171	1.6	0
458	Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050). <i>Lung Cancer</i> , <b>2021</b> , 154, 176-185	5.9	3
457	Overcoming therapy resistance in EGFR-mutant lung cancer.. <i>Nature Cancer</i> , <b>2021</b> , 2, 377-391	15.4	23
456	Canakinumab with and without pembrolizumab in patients with resectable non-small-cell lung cancer: CANOPY-N study design. <i>Future Oncology</i> , <b>2021</b> , 17, 1459-1472	3.6	3
455	The Promising Evolution of Targeted Therapeutic Strategies in Cancer. <i>Cancer Discovery</i> , <b>2021</b> , 11, 810-814	14.4	4
454	Clinical utility of plasma EGFR mutation detection with quantitative PCR in advanced lung cancer: A meta-analysis. <i>Lung Cancer</i> , <b>2021</b> , 154, 113-117	5.9	2
453	A phase II clinical study on the efficacy and predictive biomarker of pegylated recombinant arginase on hepatocellular carcinoma. <i>Investigational New Drugs</i> , <b>2021</b> , 39, 1375-1382	4.3	6
452	ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib. <i>Future Oncology</i> , <b>2021</b> , 17, 1709-1719	3.6	4
451	Economic evaluation alongside a randomised controlled trial to assess the effectiveness and cost-effectiveness of acupuncture in the management of chemotherapy-induced peripheral neuropathy. <i>Acupuncture in Medicine</i> , <b>2021</b> , 39, 41-52	1.9	0

450	The patient's perspective on treatment with dacomitinib: patient-reported outcomes from the Phase III trial ARCHER 1050. <i>Future Oncology</i> , <b>2021</b> , 17, 783-794	3.6	
449	Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX Study. <i>Journal of Thoracic Oncology</i> , <b>2021</b> , 16, 259-268	8.9	9
448	Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD-L1-positive locally advanced or metastatic non-small-cell lung cancer: KEYNOTE-042 China Study. <i>International Journal of Cancer</i> , <b>2021</b> , 148, 2313-2320	7.5	23
447	Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations. <i>Journal of Thoracic Oncology</i> , <b>2021</b> , 16, 764-773	8.9	47
446	Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. <i>Drugs</i> , <b>2021</b> , 81, 257-266	12.1	16
445	Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078). <i>Lung Cancer</i> , <b>2021</b> , 152, 7-14	5.9	13
444	Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 619-630	2.2	68
443	Efficacy and Safety of S-1 Compared With Docetaxel in Elderly Patients With Advanced NSCLC Previously Treated With Platinum-Based Chemotherapy: A Subgroup Analysis of the EAST-LC Trial. <i>JTO Clinical and Research Reports</i> , <b>2021</b> , 2, 100142	1.4	
442	Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive Cohort. <i>Journal of Thoracic Oncology</i> , <b>2021</b> , 16, 2040-2050	8.9	4
441	APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy. <i>Hepatology International</i> , <b>2021</b> , 15, 1031-1048	8.8	10
440	Plain language summary of the CROWN study comparing lorlatinib with crizotinib for people with untreated non-small cell lung cancer. <i>Future Oncology</i> , <b>2021</b> , 17, 4649-4656	3.6	
439	Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2021</b> , 7, 1617-1625	13.4	20
438	Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. <i>Journal of Thoracic Oncology</i> , <b>2021</b> , 16, 1647-1662	8.9	48
437	Genomic origin and EGFR-TKI treatments of pulmonary adenosquamous carcinoma. <i>Annals of Oncology</i> , <b>2020</b> , 31, 517-524	10.3	14
436	ATOM: A phase II study to assess efficacy of preemptive local ablative therapy to residual oligometastases of NSCLC after EGFR TKI. <i>Lung Cancer</i> , <b>2020</b> , 142, 41-46	5.9	21
435	Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer. <i>Nature Medicine</i> , <b>2020</b> , 26, 732-740	50.5	138
434	Abstract CT084: Relationship between STK11 and KEAP1 mutational status and efficacy in KEYNOTE-042: pembrolizumab monotherapy versus platinum-based chemotherapy as first-line therapy for PD-L1-positive advanced NSCLC <b>2020</b> ,		17
433	Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB). <i>Critical Reviews in Oncology/Hematology</i> , <b>2020</b> , 151, 102978	7	39

432	Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis. <i>Journal of Thoracic Oncology</i> , <b>2020</b> , 15, 637-648	8.9	35
431	Twenty-five years of Respiriology: Advances in lung cancer. <i>Respirology</i> , <b>2020</b> , 25, 26-31	3.6	2
430	Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC. <i>Journal of Thoracic Oncology</i> , <b>2020</b> , 15, 324-343	8.9	13
429	Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer. <i>Cancer</i> , <b>2020</b> , 126, 373-380	6.4	47
428	Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study of Ceritinib in ALKi-Naive Patients With ALK-Rearranged NSCLC. <i>Journal of Thoracic Oncology</i> , <b>2020</b> , 15, 609-617	8.9	15
427	First-Line Lorlatinib or Crizotinib in Advanced -Positive Lung Cancer. <i>New England Journal of Medicine</i> , <b>2020</b> , 383, 2018-2029	59.2	196
426	Pattern and impact of hepatic adverse events encountered during immune checkpoint inhibitors - A territory-wide cohort study. <i>Cancer Medicine</i> , <b>2020</b> , 9, 7052-7061	4.8	5
425	Distinct Molecular Landscape of Epstein-Barr Virus Associated Pulmonary Lymphoepithelioma-Like Carcinoma Revealed by Genomic Sequencing. <i>Cancers</i> , <b>2020</b> , 12,	6.6	10
424	Targeting -Mutant Non-Small-Cell Lung Cancer: One Mutation at a Time, With a Focus on Mutations. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 4208-4218	2.2	12
423	KRAS G12C mutations in Asia: a landscape analysis of 11,951 Chinese tumor samples. <i>Translational Lung Cancer Research</i> , <b>2020</b> , 9, 1759-1769	4.4	8
422	The impact of smoking on the effectiveness of immune checkpoint inhibitors - a systematic review and meta-analysis. <i>Acta Oncologica</i> , <b>2020</b> , 59, 96-100	3.2	5
421	Differences Between the East and the West in Managing Advanced-Stage Non-small Cell Lung Cancer. <i>Clinical Oncology</i> , <b>2020</b> , 32, e1-e9	2.8	1
420	Ambient fine particulate matter inhibits 15-lipoxygenases to promote lung carcinogenesis. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2019</b> , 38, 359	12.8	7
419	Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis. <i>Lung Cancer</i> , <b>2019</b> , 133, 96-102	5.9	53
418	Dacomitinib in the Management of Advanced Non-Small-Cell Lung Cancer. <i>Drugs</i> , <b>2019</b> , 79, 823-831	12.1	11
417	What It Takes to Improve a First-Generation Inhibitor to a Second- or Third-Generation Small Molecule. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2019</b> , 39, 196-205	7.1	8
416	Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study. <i>Journal of Thoracic Oncology</i> , <b>2019</b> , 14, 1233-1243	8.9	188
415	Final analysis of the phase III KEYNOTE-042 study: Pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy for patients (Pts) with PD-L1 positive locally advanced/metastatic NSCLC. <i>Annals of Oncology</i> , <b>2019</b> , 30, i38	10.3	18

414	Redefining Treatment Paradigms in First-line Advanced Non-Small-Cell Lung Cancer. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 4881-4887	12.9	5
413	Management of common adverse events related to first-line dacomitinib use in mutation-positive non-small-cell lung cancer: a pooled safety analysis. <i>Future Oncology</i> , <b>2019</b> , 15, 1481-1491	3.6	9
412	How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer. <i>Annals of Oncology</i> , <b>2019</b> , 30, 884-896	10.3	51
411	A Randomized Assessor-Blinded Wait-List-Controlled Trial to Assess the Effectiveness of Acupuncture in the Management of Chemotherapy-Induced Peripheral Neuropathy. <i>Integrative Cancer Therapies</i> , <b>2019</b> , 18, 1534735419836501	3	34
410	Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer. <i>Lung Cancer</i> , <b>2019</b> , 132, 126-131	5.9	17
409	IMpower150: An exploratory analysis of efficacy outcomes in patients with EGFR mutations. <i>Annals of Oncology</i> , <b>2019</b> , 30, ii48-ii49	10.3	6
408	Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. <i>Lancet Respiratory Medicine</i> , <b>2019</b> , 7, 387-401	35.1	398
407	Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. <i>Lancet, The</i> , <b>2019</b> , 393, 1819-1830	40	1272
406	Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial. <i>Journal of Thoracic Oncology</i> , <b>2019</b> , 14, 867-875	8.9	141
405	Orientation-aware plasma cell-free DNA fragmentation analysis in open chromatin regions informs tissue of origin. <i>Genome Research</i> , <b>2019</b> , 29, 418-427	9.7	81
404	Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer. <i>Future Oncology</i> , <b>2019</b> , 15, 2371-2383	3.6	2
403	Effects of dose modifications on the safety and efficacy of dacomitinib for mutation-positive non-small-cell lung cancer. <i>Future Oncology</i> , <b>2019</b> , 15, 2795-2805	3.6	14
402	The Landscape of Actionable Molecular Alterations in Immunomarker-Defined Large-Cell Carcinoma of the Lung. <i>Journal of Thoracic Oncology</i> , <b>2019</b> , 14, 1213-1222	8.9	17
401	Nivolumab + chemotherapy vs chemotherapy in EGFR-mutated NSCLC after 1L or 2L EGFR-TKIs (CheckMate 722). <i>Annals of Oncology</i> , <b>2019</b> , 30, vi126	10.3	5
400	IMpower133: Updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC). <i>Annals of Oncology</i> , <b>2019</b> , 30, v710-v711	10.3	30
399	Alectinib exposure-response (ER) in ALK-inhibitor naïve ALK-positive NSCLC patients: Pooled analysis across phase III studies.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, e20575-e20575	2.2	2
398	Randomized open-label study of M7824 versus pembrolizumab as first-line (1L) treatment in patients with PD-L1 expressing advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, TPS9114-TPS9114	2.2	3
397	Phase 2 study of brigatinib in patients (pts) with anaplastic lymphoma kinase (ALK) positive, advanced non-small cell lung cancer (NSCLC) that progressed on alectinib or ceritinib.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, TPS9115-TPS9115	2.2	3

396	Randomized open-label study of M7824 versus pembrolizumab as first-line (1L) treatment in patients with PD-L1 expressing advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, TPS127-TPS127	2.2	0
395	Comprehensive genomic profiling of circulating cell-free DNA (cfDNA) distinguishes focal amplification (amp) from aneuploidy among MET amps in diverse advanced cancer types.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 3046-3046	2.2	
394	Abstract CT199: IMpower133: Primary efficacy and safety + CNS-related adverse events in a Ph1/3 study of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC) <b>2019</b> ,		2
393	First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2019</b> , 145, 1569-1579	4.9	24
392	P2.18-01 A Multicenter, Double-Blind, Randomized, Controlled Study of Bintrafusp Alfa (M7824) in Unresectable Stage III NSCLC. <i>Journal of Thoracic Oncology</i> , <b>2019</b> , 14, S902	8.9	3
391	Overall survival (OS) from the AURA3 phase III study: Osimertinib vs platinum-pemetrexed (plt-pem) in patients (pts) with EGFR T790M advanced non-small cell lung cancer (NSCLC) and progression on a prior EGFR-tyrosine kinase inhibitor (TKI). <i>Annals of Oncology</i> , <b>2019</b> , 30, ix158	10.3	11
390	P2.14-20 ATORG-003: Dacomitinib With or Without Dose Titration as First-Line Therapy for Metastatic EGFR Mutant Non-Small Cell Lung Cancer (NSCLC). <i>Journal of Thoracic Oncology</i> , <b>2019</b> , 14, S836-S837	8.9	4
389	MA11.02 KEYNOTE-042 China Study: First-Line Pembrolizumab vs Chemotherapy in Chinese Patients with Advanced NSCLC with PD-L1 TPS ≥1%. <i>Journal of Thoracic Oncology</i> , <b>2019</b> , 14, S290-S291	8.9	7
388	Updated overall survival (OS) from extended follow up in ARCHER 1050: A randomized phase III study comparing dacomitinib with gefitinib as first-line therapy for patients (pts) with EGFR mutations. <i>Annals of Oncology</i> , <b>2019</b> , 30, ix200-ix201	10.3	9
387	Overview of current systemic management of EGFR-mutant NSCLC. <i>Annals of Oncology</i> , <b>2018</b> , 29, i3-i9	10.3	100
386	Update on International Cooperative Groups Studies in Thoracic Malignancies: The Emergence of Immunotherapy. <i>Clinical Lung Cancer</i> , <b>2018</b> , 19, 377-386	4.9	
385	Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis. <i>EBioMedicine</i> , <b>2018</b> , 29, 112-127	8.8	46
384	Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI. <i>Clinical Drug Investigation</i> , <b>2018</b> , 38, 319-331	3.2	12
383	Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis. <i>JAMA Oncology</i> , <b>2018</b> , 4, 210-216	13.4	277
382	Assessment of programmed cell death ligand-1 expression by 4 diagnostic assays and its clinicopathological correlation in a large cohort of surgical resected non-small cell lung carcinoma. <i>Modern Pathology</i> , <b>2018</b> , 31, 1381-1390	9.8	34
381	The Value of Early Depth of Response in Predicting Long-Term Outcome in EGFR-Mutant Lung Cancer. <i>Journal of Thoracic Oncology</i> , <b>2018</b> , 13, 792-800	8.9	15
380	Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials. <i>Clinical Lung Cancer</i> , <b>2018</b> , 19, e465-e479	4.9	39
379	A Review of Regimens Combining Pemetrexed With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the Treatment of Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , <b>2018</b> , 19, 27-34	4.9	17



378 Systemic Options for Second-Line Therapy and Beyond **2018**, 434-447.e5

377	Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC. <i>Journal of Thoracic Oncology</i> , <b>2018</b> , 13, 1248-1268	8.9	331
376	Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. <i>Nature Medicine</i> , <b>2018</b> , 24, 1441-1448	50.5	581
375	Epigenomic characterization of a p53-regulated 3p22.2 tumor suppressor that inhibits STAT3 phosphorylation via protein docking and is frequently methylated in esophageal and other carcinomas. <i>Theranostics</i> , <b>2018</b> , 8, 61-77	12.1	21
374	Correlation of extent of ALK FISH positivity and crizotinib efficacy in three prospective studies of ALK-positive patients with non-small-cell lung cancer. <i>Annals of Oncology</i> , <b>2018</b> , 29, 1964-1971	10.3	12
373	Clinical Application of Genomic Profiling With Circulating Tumor DNA for Management of Advanced Non-Small-cell Lung Cancer in Asia. <i>Clinical Lung Cancer</i> , <b>2018</b> , 19, e601-e608	4.9	5
372	Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , <b>2018</b> , 13, 1539-1548	8.9	85
371	Association Between Serum Folate Level and Toxicity of Capecitabine During Treatment for Colorectal Cancer. <i>Oncologist</i> , <b>2018</b> , 23, 1436-1445	5.7	4
370	Upregulation of Bcl2 in NSCLC with acquired resistance to EGFR-TKI. <i>Oncology Letters</i> , <b>2018</b> , 15, 901-907	2.6	10
369	Abstract CT114: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer (NSCLC): results of the phase 3 CheckMate 078 study <b>2018</b> ,		4
368	Dacomitinib (daco) versus gefitinib (gef) for first-line treatment of advanced NSCLC (ARCHER 1050): Final overall survival (OS) analysis.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 9004-9004	2.2	8
367	Early clearance of plasma EGFR mutations as a predictor of response to osimertinib in the AURA3 trial.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 9027-9027	2.2	18
366	Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs crizotinib (CZ) in untreated advanced ALK+ NSCLC.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 9043-9043	2.2	39
365	Refining the sensitivity of plasma cell-free DNA (cfDNA) genotyping by controlling for plasma tumor content.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 9071-9071	2.2	3
364	Population pharmacokinetics (PopPK) and exposure-response (ER) analyses to confirm the global alectinib (ALC) 600mg BID dose in the Chinese treatment-naïve population.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e21133-e21133	2.2	1
363	AXL and CDCP1: A roadmap of innate resistance in EGFR mutant NSCLC.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e24003-e24003	2.2	1
362	Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, LBA4-LBA4	2.2	117
361	Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , <b>2018</b> , 50, 691-700	5.2	30

360	Co-mutations of DNA damage response system as predictive biomarker for immune checkpoint blockades.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 3024-3024	2.2	1
359	Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6). <i>Patient</i> , <b>2018</b> , 11, 131-141	3.7	12
358	Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions. <i>Lung Cancer</i> , <b>2018</b> , 115, 12-20	5.9	98
357	Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 2244-2250	2.2	263
356	Patient-Reported Symptoms and Impact of Treatment With Osimertinib Versus Chemotherapy in Advanced Non-Small-Cell Lung Cancer: The AURA3 Trial. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 1853-1860	2.2	22
355	CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3). <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 2702-2709	2.2	221
354	Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 2251-2258	2.2	197
353	P1.13-02 eXalt3: Phase 3 Randomized Study Comparing Ensartinib to Crizotinib in Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer Patients. <i>Journal of Thoracic Oncology</i> , <b>2018</b> , 13, S582	8.9	2
352	Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study. <i>Annals of Oncology</i> , <b>2018</b> , 29, viii741	10.3	102
351	PL02.07 IMpower 133: Primary PFS, OS and Safety in a PH1/3 Study of 1L Atezolizumab + Carboplatin + Etoposide in Extensive-Stage SCLC. <i>Journal of Thoracic Oncology</i> , <b>2018</b> , 13, S185-S186	8.9	4
350	Overall survival results of ceritinib in ALKi-naïve patients with ALK-rearranged NSCLC (ASCEND-3). <i>Annals of Oncology</i> , <b>2018</b> , 29, viii745	10.3	2
349	MA26.11 Effects of Dose Modifications on the Safety and Efficacy of Dacomitinib for EGFR Mutation-Positive NSCLC. <i>Journal of Thoracic Oncology</i> , <b>2018</b> , 13, S454	8.9	4
348	Therapeutic Strategies in EGFR Mutant Non-Small Cell Lung Cancer. <i>Current Treatment Options in Oncology</i> , <b>2018</b> , 19, 58	5.4	32
347	Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , <b>2018</b> , 29, iv192-iv237	10.3	897
346	Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers. <i>Journal of Thoracic Oncology</i> , <b>2018</b> , 13, 1595-1601	8.9	69
345	First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , <b>2018</b> , 379, 2220-2229	59.2	1236
344	Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studies. <i>Lung Cancer</i> , <b>2018</b> , 126, 1-8	5.9	28
343	OA12.07 Clinical Activity of LOXO-292, a Highly Selective RET Inhibitor, in Patients with RET Fusion+ Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , <b>2018</b> , 13, S349-S350	8.9	26



342	Novel method for rapid identification of micropapillary or solid components in early-stage lung adenocarcinoma. <i>Journal of Thoracic and Cardiovascular Surgery</i> , <b>2018</b> , 156, 2310-2318.e2	1.5	9
341	Alectinib versus crizotinib in treatment-naïve anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study. <i>Annals of Oncology</i> , <b>2018</b> , 29, 2214-2222	10.3	152
340	Comutations in DNA Damage Response Pathways Serve as Potential Biomarkers for Immune Checkpoint Blockade. <i>Cancer Research</i> , <b>2018</b> , 78, 6486-6496	10.1	104
339	194TiP eXalt3: Phase 3 randomized study comparing ensartinib to crizotinib in anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC) patients. <i>Journal of Thoracic Oncology</i> , <b>2018</b> , 13, S116	8.9	2
338	30 Immunotherapy in advanced NSCLC-from the 'tsunami' of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT). <i>ESMO Open</i> , <b>2018</b> , 3, e000298	6	7
337	Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC. <i>Lung Cancer</i> , <b>2017</b> , 104, 119-125	5.9	31
336	Comparison of Segmentectomy and Lobectomy in Stage IA Adenocarcinomas. <i>Journal of Thoracic Oncology</i> , <b>2017</b> , 12, 890-896	8.9	43
335	The Role of Radiotherapy in Epidermal Growth Factor Receptor Mutation-positive Patients with Oligoprogression: A Matched-cohort Analysis. <i>Clinical Oncology</i> , <b>2017</b> , 29, 568-575	2.8	25
334	Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. <i>Lancet Oncology</i> , <b>2017</b> , 18, 874-886	21.7	314
333	Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival. <i>Journal of the National Cancer Institute</i> , <b>2017</b> , 109,	9.7	136
332	The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy. <i>Cancer Treatment Reviews</i> , <b>2017</b> , 55, 181-189	14.4	9
331	P3.02c-038 First-Line Atezolizumab plus Chemotherapy in Chemotherapy-Naïve Patients with Advanced NSCLC: A Phase III Clinical Program. <i>Journal of Thoracic Oncology</i> , <b>2017</b> , 12, S1296-S1297	8.9	3
330	Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 629-640	59.2	1811
329	EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6. <i>British Journal of Cancer</i> , <b>2017</b> , 116, 175-185	8.7	61
328	Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 412-420	2.2	174
327	Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , <b>2017</b> , 18, 1454-1466	21.7	559
326	Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer). <i>Annals of Oncology</i> , <b>2017</b> , 28, 2698-2706	10.3	51
325	Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis. <i>Journal of Thoracic Oncology</i> , <b>2017</b> , 12, 403-407	8.9	432

324	Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 4027-4034	2.2	97
323	Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 1403-1410	2.2	198
322	Blood-based tumor biomarkers in lung cancer for detection and treatment. <i>Translational Lung Cancer Research</i> , <b>2017</b> , 6, 648-660	4.4	35
321	Comparison of 22C3 PD-L1 Expression between Surgically Resected Specimens and Paired Tissue Microarrays in Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , <b>2017</b> , 12, 1536-1543	8.9	41
320	De-novo and acquired resistance to immune checkpoint targeting. <i>Lancet Oncology</i> , <b>2017</b> , 18, e731-e741	17.1	383
319	A phase 2 study of the efficacy and biomarker on the combination of transarterial chemoembolization and axitinib in the treatment of inoperable hepatocellular carcinoma. <i>Cancer</i> , <b>2017</b> , 123, 3977-3985	6.4	13
318	Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. <i>Annals of Oncology</i> , <b>2017</b> , 28, 270-277	10.3	296
317	Overview of Thoracic Oncology Trials in Cooperative Groups Around the Globe. <i>Clinical Lung Cancer</i> , <b>2017</b> , 18, 5-12	4.9	2
316	Systematic evaluation of circulating inflammatory markers for hepatocellular carcinoma. <i>Liver International</i> , <b>2017</b> , 37, 280-289	7.9	28
315	Is there significance in identification of non-predominant micropapillary or solid components in early-stage lung adenocarcinoma?. <i>Interactive Cardiovascular and Thoracic Surgery</i> , <b>2017</b> , 24, 121-125	1.8	14
314	Primary PFS and safety analyses of a randomized phase III study of carboplatin + paclitaxel +/- bevacizumab, with or without atezolizumab in 1L non-squamous metastatic nscl (IMPOWER150). <i>Annals of Oncology</i> , <b>2017</b> , 28, xi31	10.3	17
313	Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 829-838	59.2	1221
312	OA 10.01 Detection of EGFR mutations from plasma ctDNA in the osimertinib Phase III trial (AURA3): comparison of three plasma assays. <i>Journal of Thoracic Oncology</i> , <b>2017</b> , 12, S1771	8.9	5
311	P3.01-039 Sequential Afatinib-Osimertinib Therapy in EGFR Mutation-Positive (EGFRm+) NSCLC: Analysis of Time on Treatment and OS. <i>Journal of Thoracic Oncology</i> , <b>2017</b> , 12, S2215-S2216	8.9	4
310	P1.04-008 POSEIDON: A Phase 3 Study of First-Line Durvalumab + Tremelimumab + Chemotherapy vs Chemotherapy Alone in Metastatic NSCLC. <i>Journal of Thoracic Oncology</i> , <b>2017</b> , 12, S1975	8.9	12
309	FOXP3 promotes tumor growth and metastasis by activating Wnt/β-catenin signaling pathway and EMT in non-small cell lung cancer. <i>Molecular Cancer</i> , <b>2017</b> , 16, 124	42.1	174
308	Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer. <i>ESMO Open</i> , <b>2017</b> , 2, e000219	6	62
307	Impact of MET inhibitors on survival among patients (pts) with MET exon 14 mutant (METdel14) non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 8511-8511	2.2	21

306	CNS response to osimertinib in patients (pts) with T790M-positive advanced NSCLC: Data from a randomized phase III trial (AURA3).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 9005-9005	2.2	41
305	Baseline frequency of brain metastases and outcomes with multikinase inhibitor therapy in patients with RET-rearranged lung cancers.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 9069-9069	2.2	6
304	Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): A randomized, open-label phase III trial.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, LBA9007-LBA9007	2.2	3
303	Alectinib versus crizotinib in treatment-naïve advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, LBA9008-LBA9008	2.2	6
302	eXalt3: A phase III study of ensartinib (X-396) in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, TPS8578-TPS8578	2.2	5
301	Phase I/III trial of atezolizumab with carboplatin and etoposide in ES-SCLC in first-line setting (IMpower133).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, TPS8584-TPS8584	2.2	2
300	Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): A randomized, open-label phase III trial.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, LBA9007-LBA9007	2.2	17
299	Alectinib versus crizotinib in treatment-naïve advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, LBA9008-LBA9008	2.2	11
298	A study on thromboembolism of patients with pancreatic cancer.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 262-262	2.2	1
297	Clinical significance of 22C3-PD-L1 IHC expression in surgically resected non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e20507-e20507	2.2	
296	Single-Port Video-Assisted Thoracoscopic Major Lung Resections: Experience with 150 Consecutive Cases. <i>Thoracic and Cardiovascular Surgeon</i> , <b>2016</b> , 64, 348-53	1.6	53
295	Clinician Perspectives on Current Issues in Lung Cancer Drug Development. <i>Journal of Thoracic Oncology</i> , <b>2016</b> , 11, 1387-96	8.9	6
294	Gefitinib/chemotherapy vs chemotherapy in EGFR mutation-positive NSCLC after progression on 1st line gefitinib (IMPRESS study): Final overall survival (OS) analysis. <i>Annals of Oncology</i> , <b>2016</b> , 27, vi416	10.3	9
293	Afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC): overall survival (OS) data from the phase IIb trial LUX-Lung 7 (LL7). <i>Annals of Oncology</i> , <b>2016</b> , 27, vi580	10.3	6
292	Epigenetic inactivation of the CpG demethylase TET1 as a DNA methylation feedback loop in human cancers. <i>Scientific Reports</i> , <b>2016</b> , 6, 26591	4.9	66
291	Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 2866-73	2.2	238
290	MINI01.01: Whole Body and Intracranial Efficacy of Ceritinib in ALK-inhibitor Naïve Patients with ALK+ NSCLC and Brain Metastases: Results of ASCEND 1 and 3. <i>Journal of Thoracic Oncology</i> , <b>2016</b> , 11, S256	8.9	10
289	Phase III clinical trials in chemotherapy-naïve patients with advanced NSCLC assessing the combination of atezolizumab and chemotherapy. <i>Annals of Oncology</i> , <b>2016</b> , 27, vi451	10.3	4

288	Phase 2 study of ceritinib in ALK-negative patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC): Whole body responses in the overall pt group and in pts with baseline brain metastases (BM). <i>Annals of Oncology</i> , <b>2016</b> , 27, vi416	10.3	14
287	195TiP: Pembrolizumab (MK-3475) versus platinum-based chemotherapy for PD-L1+ NSCLC in a phase 3, randomized, open-label study: KEYNOTE-042. <i>Journal of Thoracic Oncology</i> , <b>2016</b> , 11, S142	8.9	2
286	141PD: Whole body and intracranial efficacy of ceritinib in patients (pts) with crizotinib (CRZ) pretreated, ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) and baseline brain metastases (BM): Results from ASCEND-1 and ASCEND-2 trials. <i>Journal of Thoracic Oncology</i> , <b>2016</b> , 11, S118-S119	8.9	13
285	Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer. <i>Lung Cancer</i> , <b>2016</b> , 98, 1-8	5.9	16
284	PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 953-62	2.2	254
283	Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials. <i>Annals of Oncology</i> , <b>2016</b> , 27, 423-9	10.3	38
282	Tumorigenesis of smoking carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone is related to its ability to stimulate thromboxane synthase and enhance stemness of non-small cell lung cancer stem cells. <i>Cancer Letters</i> , <b>2016</b> , 370, 198-206	9.9	12
281	Cancer Genomics: Diversity and Disparity Across Ethnicity and Geography. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 91-101	2.2	107
280	Special Issue on Global Cancer Medicine. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 1-2	2.2	46
279	Scientific Advances in Lung Cancer 2015. <i>Journal of Thoracic Oncology</i> , <b>2016</b> , 11, 613-638	8.9	164
278	First-Line Pemetrexed plus Cisplatin followed by Gefitinib Maintenance Therapy versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer: Final Overall Survival Results from a Randomized Phase 3 Study. <i>Journal of Thoracic Oncology</i> , <b>2016</b> , 11, 370-9	8.9	11
277	MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 3048-56	12.9	226
276	First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases. <i>Journal of Thoracic Oncology</i> , <b>2016</b> , 11, 380-90	8.9	240
275	Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations. <i>Journal of Thoracic Oncology</i> , <b>2016</b> , 11, 545-55	8.9	63
274	First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer: The ASPIRATION Study. <i>JAMA Oncology</i> , <b>2016</b> , 2, 305-12	13.4	164
273	Are we ready for immune checkpoint inhibitors for advanced non-small-cell lung cancer?. <i>Lancet, The</i> , <b>2016</b> , 387, 1488-1490	40	8
272	First-line afatinib (A) vs gefitinib (G) for patients (pts) with EGFR mutation positive (EGFRm+) NSCLC (LUX-Lung 7): Patient-reported outcomes (PROs) and impact of dose modifications on efficacy and adverse events (AEs).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 9046-9046	2.2	10
271	Phase 3 study of first-line crizotinib vs pemetrexed/cisplatin/carboplatin (PCC) in East Asian patients (pts) with ALK+ advanced non-squamous non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 9058-9058	2.2	6

270	Crizotinib vs chemotherapy in ALK+ advanced non-small cell lung cancer (NSCLC): Final survival results from PROFILE 1007.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 9066-9066	2.2	8
269	ALK FISH positivity and crizotinib efficacy in patients (pts) with non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 9062-9062	2.2	
268	Whole body and intracranial efficacy of ceritinib in ALK-inhibitor (ALKi)-naive patients (pts) with ALK-rearranged (ALK+) NSCLC and baseline (BL) brain metastases (BM): Results from ASCEND-1 and -3.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e20520-e20520	2.2	
267	Phase III clinical trials of atezolizumab combined with chemotherapy in chemotherapy-naive patients with advanced NSCLC.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, TPS9103-TPS9103	2.2	
266	Ceritinib vs chemotherapy (CT) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with CT and crizotinib (CRZ): Results from the confirmatory phase 3 ASCEND-5 study. <i>Annals of Oncology</i> , <b>2016</b> , 27, vi579	10.3	11
265	Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 2858-65	2.2	171
264	The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016. <i>Journal of Thoracic Oncology</i> , <b>2016</b> , 11, 946-63	8.9	145
263	192TiP: NEPTUNE: A global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy versus standard of care (SoC) platinum-based chemotherapy in the first-line treatment of patients (pts) with advanced or metastatic NSCLC. <i>Journal of Thoracic Oncology</i> , <b>2016</b> , 11, S118-S119	8.9	27
262	138PD: Impact of dose adjustment on the safety and efficacy of afatinib in patients (pts) with advanced EGFR mutation-positive non-small cell lung cancer (NSCLC): Post-hoc analyses of LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6). <i>Journal of Thoracic Oncology</i> , <b>2016</b> , 11, S116-S117	8.9	2
261	140PD: LUX-Lung 7: A Phase IIb, global, randomised, open-label trial of afatinib vs gefitinib as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations. <i>Journal of Thoracic Oncology</i> , <b>2016</b> , 11, S117-S118	8.9	3
260	Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. <i>Lancet Oncology</i> , <b>2016</b> , 17, 577-89	21.7	691
259	Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials. <i>Annals of Oncology</i> , <b>2016</b> , 27, 2103-2110	10.3	128
258	A Randomized Phase 2 Study Comparing the Combination of Ficluzumab and Gefitinib with Gefitinib Alone in Asian Patients with Advanced Stage Pulmonary Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , <b>2016</b> , 11, 1736-44	8.9	36
257	Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. <i>Lancet Oncology</i> , <b>2015</b> , 16, 141-51	21.7	1081
256	Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 3196-203	12.9	341
255	Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. <i>Lancet Oncology</i> , <b>2015</b> , 16, 990-8	21.7	291
254	2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer. <i>Annals of Oncology</i> , <b>2015</b> , 26, 1573-88	10.3	225
253	EGFR mutation testing practices within the Asia Pacific region: results of a multicenter diagnostic survey. <i>Journal of Thoracic Oncology</i> , <b>2015</b> , 10, 438-45	8.9	115



252	First-line crizotinib in ALK-positive lung cancer. <i>New England Journal of Medicine</i> , <b>2015</b> , 372, 782	59.2	18
251	Novel targeted agents for the treatment of lung cancer in China. <i>Cancer</i> , <b>2015</b> , 121 Suppl 17, 3089-96	6.4	7
250	Antineoplastic effects of 15(S)-hydroxyeicosatetraenoic acid and 13-S-hydroxyoctadecadienoic acid in non-small cell lung cancer. <i>Cancer</i> , <b>2015</b> , 121 Suppl 17, 3130-45	6.4	15
249	Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, 830-8	21.7	551
248	Estrogen receptor alpha promotes smoking-carcinogen-induced lung carcinogenesis via cytochrome P450 1B1. <i>Journal of Molecular Medicine</i> , <b>2015</b> , 93, 1221-33	5.5	11
247	Non-small-cell lung cancer. <i>Nature Reviews Disease Primers</i> , <b>2015</b> , 1, 15009	51.1	352
246	Crizotinib in the management of advanced-stage non-small-cell lung cancer. <i>Future Oncology</i> , <b>2015</b> , 11, 735-45	3.6	10
245	Profiling of Oncogenic Driver Events in Lung Adenocarcinoma Revealed MET Mutation as Independent Prognostic Factor. <i>Journal of Thoracic Oncology</i> , <b>2015</b> , 10, 1292-1300	8.9	40
244	Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens. <i>Journal of Thoracic Oncology</i> , <b>2015</b> , 10, 1745-53	8.9	74
243	Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2015</b> , 112, E1317-25	11.5	392
242	A randomized Phase 3 study comparing first-line pemetrexed plus cisplatin followed by gefitinib maintenance (PC/G) with gefitinib monotherapy (G) in East Asian patients (pts) with locally advanced or metastatic nonsquamous non-small cell lung cancer (nSqNSCLC): Final survival results.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 2041-2041	2.2	1
241	The impact on overall survival (OS) of first-line gefitinib (G) and erlotinib (E) and of clinical factors in advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor mutations (EGFR mut) based on meta-analysis of 1,231 patients (pts) enrolled in 6 major clinical trials. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 2073-2073	2.2	4
240	Impact of crizotinib on patient-reported general health status compared with chemotherapy in patients with no prior systemic treatment for advanced non-squamous ALK-positive non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 8101-8101	2.2	4
239	TIGER 1: A randomized, open-label, phase 2/3 study of rociletinib (CO-1686) or erlotinib as first-line treatment for EGFR-mutant non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, TPS8108-TPS8108	2.2	1
238	Strategy on Patients with EGFR Mutation <b>2015</b> , 133-145		
237	A phase II clinical trial on combined axitinib and transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC): Final results and evaluation of clinical predictor for response.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 4073-4073	2.2	
236	2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , <b>2014</b> , 25, 1462-74	10.3	268
235	Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial. <i>Lancet Oncology, The</i> , <b>2014</b> , 15, 1433-1441	21.7	92

234	Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2014</b> , 15, 1369-78	21.7	109
233	First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: a randomised, phase 3 trial. <i>European Journal of Cancer</i> , <b>2014</b> , 50, 2219-30	7.5	29
232	Clinical genotyping and efficacy outcomes: exploratory biomarker data from the phase II ABIGAIL study of first-line bevacizumab plus chemotherapy in non-squamous non-small-cell lung cancer. <i>Lung Cancer</i> , <b>2014</b> , 86, 67-72	5.9	13
231	Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology. <i>Clinical Lung Cancer</i> , <b>2014</b> , 15, 173-81	4.9	50
230	A REVELation in non-small-cell lung cancer treatment?. <i>Lancet, The</i> , <b>2014</b> , 384, 640-2	4.0	5
229	Afatinib in the treatment of EGFR mutation-positive NSCLC--a network meta-analysis. <i>Lung Cancer</i> , <b>2014</b> , 85, 230-8	5.9	40
228	First-Line Crizotinib Vs Pemetrexed + Cisplatin/Carboplatin in Asian Patients with Advanced Alk+ Nscl in Profile 1014. <i>Annals of Oncology</i> , <b>2014</b> , 25, v2	10.3	3
227	Detection of Epidermal Growth Factor Receptor (EGFR) Mutations in Circulating Cell-Free DNA in Two Phase III Studies (LUX-Lung 3 and LUX-Lung 6) of Afatinib vs Platinum-Based Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer. <i>American Journal of Clinical Pathology</i> , <b>2014</b> , 142, A182-A182	1.9	
226	The Yin-Yang of guidelines and disparity. <i>Oncologist</i> , <b>2014</b> , 19, 1011	5.7	1
225	Parents' Involvement in Childcare: Do Parental and Work Identities Matter?. <i>Psychology of Women Quarterly</i> , <b>2014</b> , 38, 475-489	3.2	21
224	Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 2059-66	2.2	105
223	Dacomitinib for the treatment of advanced or metastatic non-small-cell lung cancer. <i>Future Oncology</i> , <b>2014</b> , 10, 813-22	3.6	10
222	Unresectable hepatocellular carcinoma: randomized controlled trial of transarterial ethanol ablation versus transcatheter arterial chemoembolization. <i>Radiology</i> , <b>2014</b> , 270, 607-20	20.5	31
221	2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. <i>Annals of Oncology</i> , <b>2014</b> , 25, 1475-84	10.3	174
220	Randomized phase II study of two intercalated combinations of eribulin mesylate and erlotinib in patients with previously treated advanced non-small-cell lung cancer. <i>Annals of Oncology</i> , <b>2014</b> , 25, 1578-84	10.3	9
219	First-line crizotinib versus chemotherapy in ALK-positive lung cancer. <i>New England Journal of Medicine</i> , <b>2014</b> , 371, 2167-77	59.2	2116
218	Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 1383-92	12.9	121
217	Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLC. <i>Journal of Cellular and Molecular Medicine</i> , <b>2014</b> , 18, 1519-39	5.6	28

216	A correlative biomarker analysis of the combination of bevacizumab and carboplatin-based chemotherapy for advanced nonsquamous non-small-cell lung cancer: results of the phase II randomized ABIGAIL study (BO21015). <i>Journal of Thoracic Oncology</i> , <b>2014</b> , 9, 848-55	8.9	43
215	Spacer application for prostate cancer radiation therapy. <i>Future Oncology</i> , <b>2014</b> , 10, 851-64	3.6	17
214	Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. <i>Annals of Oncology</i> , <b>2014</b> , 25, 1681-1690	10.3	208
213	Targeting epidermal growth factor receptor in the management of lung cancer. <i>Seminars in Oncology</i> , <b>2014</b> , 41, 101-9	5.5	19
212	Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan-ASia Study (IPASS). <i>Lung Cancer</i> , <b>2014</b> , 83, 174-81	5.9	36
211	CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance. <i>Journal of Clinical Investigation</i> , <b>2014</b> , 124, 3003-15	15.9	70
210	Overall survival (OS) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut): Pooled analysis of two large open-label phase III studies (LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6]) comparing gefitinib with chemotherapy (CT). <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 8004-8004	2.2	22
209	Randomized, double-blinded study of dacomitinib, an irreversible pan-human epidermal growth factor receptor (HER) inhibitor, versus erlotinib for second-line/third-line therapy of locally advanced/metastatic non-small cell lung cancer (ARCHER 1009).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 8018-8018	2.2	10
208	Comparison is beyond IPASS and OPTIMAL. <i>Hong Kong Medical Journal</i> , <b>2014</b> , 20, 176-7	0.7	
207	Management of non-small-cell lung cancer: recent developments. <i>Lancet, The</i> , <b>2013</b> , 382, 709-19	40	563
206	Intercalated chemotherapy and erlotinib: a viable first-line option for patients with advanced NSCLC? - authors' reply. <i>Lancet Oncology, The</i> , <b>2013</b> , 14, e438-e439	21.7	1
205	Treating patients with EGFR-sensitizing mutations: first line or second line--is there a difference?. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 1081-8	2.2	89
204	Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients. <i>Cancer</i> , <b>2013</b> , 119, 2383-90	6.4	36
203	Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 3327-34	2.2	2262
202	Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 3342-50	2.2	222
201	Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: post hoc analyses from the IPASS study. <i>Lung Cancer</i> , <b>2013</b> , 81, 280-7	5.9	39
200	32 LUX-Lung 3: Symptom and health-related quality of life results from a randomized phase III study in 1st-line advanced NSCLC patients harbouring EGFR mutations. <i>Lung Cancer</i> , <b>2013</b> , 79, S11	5.9	2
199	Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC). <i>Cancer Treatment Reviews</i> , <b>2013</b> , 39, 252-60	14.4	57

198	Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. <i>New England Journal of Medicine</i> , <b>2013</b> , 368, 2385-94	59.2	2594
197	Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. <i>Lancet Oncology</i> , <b>2013</b> , 14, 777-86	21.7	237
196	Phase 3 Randomized Study (ARCHER 1050) of 1st-Line Dacomitinib vs Gefitinib for Advanced NSCLC with EGFR Mutation(S). <i>Annals of Oncology</i> , <b>2013</b> , 24, ix44	10.3	3
195	Targeted therapy for hepatocellular carcinoma: current status and future direction. <i>Clinical Investigation</i> , <b>2013</b> , 3, 83-93		
194	Thromboxane A2 receptor $\beta$ promotes tumor growth through an autoregulatory feedback pathway. <i>Journal of Molecular Cell Biology</i> , <b>2013</b> , 5, 380-90	6.3	18
193	Detection of ALK rearrangement by immunohistochemistry in lung adenocarcinoma and the identification of a novel EML4-ALK variant. <i>Journal of Thoracic Oncology</i> , <b>2013</b> , 8, 883-91	8.9	56
192	Epidermal growth factor receptor inhibition in lung cancer: status 2012. <i>Journal of Thoracic Oncology</i> , <b>2013</b> , 8, 373-84	8.9	99
191	Epigenomic analysis of lung adenocarcinoma reveals novel DNA methylation patterns associated with smoking. <i>OncoTargets and Therapy</i> , <b>2013</b> , 6, 1471-9	4.4	19
190	Detection of EGFR-activating mutations from plasma DNA as a potent predictor of survival outcomes in FASTACT 2: A randomized phase III study on intercalated combination of erlotinib (E) and chemotherapy (C).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 8021-8021	2.2	6
189	Phase III randomized, open label study (ARCHER 1050) of first-line dacomitinib (D) versus gefitinib (G) for advanced (adv) non-small cell lung cancer (NSCLC) in patients (pts) with epidermal growth factor receptor (EGFR) activating mutation(s).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, TPS8123-TPS8123	2.2	5
188	Phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer: evaluation of patients recruited from mainland China. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2012</b> , 8, 232-43	1.9	33
187	Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung. <i>Cancer</i> , <b>2012</b> , 118, 1032-9	6.4	52
186	An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma. <i>Investigational New Drugs</i> , <b>2012</b> , 30, 387-94	4.3	52
185	EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects. <i>Cancer Treatment Reviews</i> , <b>2012</b> , 38, 416-30	14.4	97
184	Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , <b>2012</b> , 13, 500-4	4.9	72
183	LUX-lung 3: A randomized, open-label, phase III study of afatinib vs pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. <i>Lung Cancer</i> , <b>2012</b> , 77, S25-S26	5.9	16
182	Clinical outcomes with erlotinib in patients with epidermal growth factor receptor mutation. <i>Drugs</i> , <b>2012</b> , 72 Suppl 1, 3-10	12.1	5
181	Combining chemotherapy with epidermal growth factor receptor inhibition in advanced non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , <b>2012</b> , 4, 173-81	5.4	14

180	Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status. <i>PLoS ONE</i> , <b>2012</b> , 7, e40109	3.7	136
179	Dacomitinib (PF-00299804), An Irreversible Pan-Her Tyrosine Kinase Inhibitor (TKI), For First-Line Treatment of EGFR-Mutant or Her2-Mutant or -Amplified Lung Cancers. <i>Annals of Oncology</i> , <b>2012</b> , 23, ix400-ix401	10.3	4
178	Activity of Afatinib in Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations in Lux-Lung 3, A Phase III Trial of Afatinib or Cisplatin/Pemetrexed in EGFR Mutation-Positive Lung Cancer. <i>Annals of Oncology</i> , <b>2012</b> , 23, ix410-ix411	10.3	4
177	Final Analysis of Overall Survival (OS) in the IPASS, an International Multicenter Phase III Study on Gefitinib and Carboplatin/Paclitaxel for Treatment-na <sup>ve</sup> NSCLC Patients. <i>Japanese Journal of Lung Cancer</i> , <b>2012</b> , 52, 153-160	0.1	2
176	A study of circulating interleukin 10 in prognostication of unresectable hepatocellular carcinoma. <i>Cancer</i> , <b>2012</b> , 118, 3984-92	6.4	43
175	Management of hepatocellular carcinoma: beyond sorafenib. <i>Current Oncology Reports</i> , <b>2012</b> , 14, 257-66.	3	22
174	Use of antiviral therapy in surveillance: impact on outcome of hepatitis B-related hepatocellular carcinoma. <i>Liver International</i> , <b>2012</b> , 32, 271-8	7.9	14
173	Smoking history as a predictive factor of treatment response in advanced non-small-cell lung cancer: a systematic review. <i>Clinical Lung Cancer</i> , <b>2012</b> , 13, 239-51	4.9	24
172	Differences in outcome and toxicity between Asian and caucasian patients with lung cancer treated with systemic therapy. <i>Future Oncology</i> , <b>2012</b> , 8, 451-62	3.6	35
171	A novel 19q13 nucleolar zinc finger protein suppresses tumor cell growth through inhibiting ribosome biogenesis and inducing apoptosis but is frequently silenced in multiple carcinomas. <i>Molecular Cancer Research</i> , <b>2012</b> , 10, 925-36	6.6	37
170	EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas. <i>Oncologist</i> , <b>2012</b> , 17, 978-85	5.7	131
169	Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2012</b> , 7, 115-21	8.9	180
168	A randomized placebo-controlled phase III study of intercalated erlotinib with gemcitabine/platinum in first-line advanced non-small cell lung cancer (NSCLC): FASTACT-II.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 7519-7519	2.2	12
167	LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, LBA7500-LBA7500	2.2	12
166	ARCHER: Dacomitinib (D; PF-00299804) versus erlotinib (E) for advanced (adv) non-small cell lung cancer (NSCLC): A randomized double-blind phase III study.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, TPS7615-TPS7615	2.2	10
165	LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, LBA7500-LBA7500	2.2	53
164	A Randomized Phase (PH) 2 Study with Exploratory Biomarker Analysis of Ficlatusumab (F) A Humanized Hepatocyte Growth Factor (HGF) Inhibitory MAB in Combination with Gefitinib (G) Versus G in Asian Patients (PTS) with Lung Adenocarcinoma (LA). <i>Annals of Oncology</i> , <b>2012</b> , 23, ix391	10.3	18
163	Biomarker Analyses and Overall Survival (OS) from the Randomized, Placebo-Controlled, Phase 3, Fastact-2 Study of Intercalated Erlotinib with First-Line Chemotherapy in Advanced Non-Small-Cell Lung Cancer (NSCLC). <i>Annals of Oncology</i> , <b>2012</b> , 23, ix400-ix401	10.3	10



162	9132 POSTER Efficacy Outcomes in First-line Treatment of Advanced NSCLC With Gefitinib (G) vs Carboplatin/paclitaxel (C/P) by Epidermal Growth Factor Receptor (EGFR) Gene-copy Number Score and by Most Common EGFR Mutation Subtypes [Exploratory Data From IPASS. <i>European Journal of Cancer</i> , <b>2011</b> , 47, S633	7.5	8
161	Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence. <i>Lung Cancer</i> , <b>2011</b> , 71, 249-57	5.9	92
160	Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: implications for clinical practice and open issues. <i>Lung Cancer</i> , <b>2011</b> , 72, 3-8	5.9	35
159	Lung cancer in never smokers: change of a mindset in the molecular era. <i>Lung Cancer</i> , <b>2011</b> , 72, 9-15	5.9	65
158	Personalized medicine in lung cancer: what we need to know. <i>Nature Reviews Clinical Oncology</i> , <b>2011</b> , 8, 661-8	19.4	118
157	INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer. <i>BMC Cancer</i> , <b>2011</b> , 11, 430	4.8	59
156	Data mining on DNA sequences of hepatitis B virus. <i>IEEE/ACM Transactions on Computational Biology and Bioinformatics</i> , <b>2011</b> , 8, 428-40	3	27
155	Piloting electronic self report symptom assessment - Cancer (ESRA-C) in Hong Kong: a mixed method approach. <i>European Journal of Oncology Nursing</i> , <b>2011</b> , 15, 325-34	2.8	7
154	Ethnic differences in survival outcome in patients with advanced stage non-small cell lung cancer: results of a meta-analysis of randomized controlled trials. <i>Journal of Thoracic Oncology</i> , <b>2011</b> , 6, 1030-8	8.9	63
153	Prospective validation of the Chinese University Prognostic Index and comparison with other staging systems for hepatocellular carcinoma in an Asian population. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2011</b> , 26, 340-7	4	64
152	Targeted therapy: an evolving world of lung cancer. <i>Respirology</i> , <b>2011</b> , 16, 13-21	3.6	14
151	4-Methylnitrosamino-1-3-pyridyl-1-butanone (NNK) promotes lung cancer cell survival by stimulating thromboxane A2 and its receptor. <i>Oncogene</i> , <b>2011</b> , 30, 106-16	9.2	42
150	Inhibition of c-Met downregulates TIGAR expression and reduces NADPH production leading to cell death. <i>Oncogene</i> , <b>2011</b> , 30, 1127-34	9.2	50
149	Efficacy of bevacizumab with cisplatin and gemcitabine in Asian patients with advanced or recurrent non-squamous non-small cell lung cancer who have not received prior chemotherapy: a substudy of the Avastin in Lung trial. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2011</b> , 7 Suppl 2, 4-12	1.9	31
148	Anti-invasion, anti-proliferation and anoikis-sensitization activities of lapatinib in nasopharyngeal carcinoma cells. <i>Investigational New Drugs</i> , <b>2011</b> , 29, 1241-52	4.3	16
147	Prediction of outcome in cancer patients with febrile neutropenia: a prospective validation of the Multinational Association for Supportive Care in Cancer risk index in a Chinese population and comparison with the Talcott model and artificial neural network. <i>Supportive Care in Cancer</i> , <b>2011</b> , 19, 1625-35	3.9	32
146	Immediate Versus Delayed Treatment with EGFR Tyrosine Kinase Inhibitors after First-line Therapy in Advanced Non-small-cell Lung CANCER. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , <b>2011</b> , 23, 112-7	3.8	2
145	Moderate coffee consumption reduces the risk of hepatocellular carcinoma in hepatitis B chronic carriers: a case-control study. <i>Journal of Epidemiology and Community Health</i> , <b>2011</b> , 65, 556-8	5.1	34

144	Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 2866-74	2.2	1102
143	Reviewing the safety of erlotinib in non-small cell lung cancer. <i>Expert Opinion on Drug Safety</i> , <b>2011</b> , 10, 147-57	4.1	18
142	9003 ORAL Biomarker Analysis in BO21015, a Phase II Randomised Study of First-line Bevacizumab (BEV) Combined With Carboplatin-gemcitabine (CG) or Carboplatin-paclitaxel (CP) in Patients (pts) With Advanced or Recurrent Non-squamous Non-small Cell Lung Cancer (NSCLC). <i>European Journal of Cancer</i> , <b>2011</b> , 47, S592	7.5	4
141	1st ESMO Consensus Conference in lung cancer; Lugano 2010: small-cell lung cancer. <i>Annals of Oncology</i> , <b>2011</b> , 22, 1973-1980	10.3	42
140	A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer. <i>Annals of Oncology</i> , <b>2011</b> , 22, 2057-2067	10.3	73
139	Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010. <i>Annals of Oncology</i> , <b>2011</b> , 22, 1507-1519	10.3	98
138	Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005.. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 7514-7514	2.2	82
137	MAGRIT phase III trial: MAGE-A3 antigen-specific cancer immunotherapy (ASCI) as adjuvant therapy in patients with completely resected stage IB-IIIA NSCLC.. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, TPS210-TPS210	2.2	11
136	Randomized phase II study of ficlatuzumab (formerly AV-299), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb) in combination with gefitinib (G) in Asian patients (pts) with NSCLC.. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, TPS213-TPS213	2.2	11
135	The significance of serum interleukin-10 on the outcome of unresectable hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 205-205	2.2	1
134	Living with imperfection. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 191-2	2.2	30
133	Personalized medicine for non-small-cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , <b>2010</b> , 10, 1603-1611	3.1	10
132	Aberrant concentrations of liver-derived plasma albumin mRNA in liver pathologies. <i>Clinical Chemistry</i> , <b>2010</b> , 56, 82-9	5.5	15
131	Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 1660-5	2.2	336
130	Lung cancer working group report. <i>Japanese Journal of Clinical Oncology</i> , <b>2010</b> , 40 Suppl 1, i7-12	2.8	17
129	PPARgamma activation extinguishes smoking carcinogen by inhibiting NNK-mediated proliferation. <i>American Journal of Respiratory Cell and Molecular Biology</i> , <b>2010</b> , 42, 113-22	5.7	14
128	15-Lipoxygenases and its metabolites 15(S)-HETE and 13(S)-HODE in the development of non-small cell lung cancer. <i>Thorax</i> , <b>2010</b> , 65, 321-6	7.3	54
127	PARP inhibition in BRCA-mutated breast and ovarian cancers. <i>Lancet, The</i> , <b>2010</b> , 376, 211-3	40	38

126	Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 744-52	2.2	424
125	Population-based differences in treatment outcome following anticancer drug therapies. <i>Lancet Oncology, The</i> , <b>2010</b> , 11, 75-84	21.7	110
124	Molecularly targeted therapy: when to stop and when to continue?. <i>Lancet Oncology, The</i> , <b>2010</b> , 11, 709-11.7	5	
123	Chemotherapy response in East Asian non-small cell lung cancer patients harboring wild-type or activating mutation of epidermal growth factor receptors. <i>Journal of Thoracic Oncology</i> , <b>2010</b> , 5, 1424-9	8.9	26
122	Efficacy and safety of erlotinib in 1242 East/South-East Asian patients with advanced non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2010</b> , 5, 1609-15	8.9	29
121	A phase II study of fenretinide in patients with hormone refractory prostate cancer: a trial of the Cancer Therapeutics Research Group. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2010</b> , 66, 845-50	3.5	30
120	Anticancer efficacy of 5F in NNK-induced lung cancer development of A/J mice and human lung cancer cells. <i>Journal of Molecular Medicine</i> , <b>2010</b> , 88, 1265-76	5.5	16
119	Genetic evolution of epidermal growth factor receptor in adenocarcinoma with a bronchioloalveolar carcinoma component. <i>Clinical Lung Cancer</i> , <b>2010</b> , 11, 160-8	4.9	6
118	Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. <i>Cancer Cell</i> , <b>2010</b> , 17, 77-88	24.3	816
117	Thromboxane synthase suppression induces lung cancer cell apoptosis via inhibiting NF-B. <i>Experimental Cell Research</i> , <b>2010</b> , 316, 3468-77	4.2	15
116	Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis. <i>Journal of Cellular and Molecular Medicine</i> , <b>2010</b> , 14, 51-69	5.6	110
115	Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 7500-7500	2.2	61
114	Randomized, open-label phase II study of motesanib or bevacizumab in combination with paclitaxel and carboplatin (P/C) for advanced nonsquamous non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 7528-7528	2.2	10
113	Efficacy and safety of PF-00299804 (PF299), an oral, irreversible, pan-human epidermal growth factor receptor (pan-HER) tyrosine kinase inhibitor (TKI), as first-line treatment (tx) of selected patients (pts) with advanced (adv) non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 7527-7527	2.2	8
112	New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 446-52	2.2	205
111	CMTM3, located at the critical tumor suppressor locus 16q22.1, is silenced by CpG methylation in carcinomas and inhibits tumor cell growth through inducing apoptosis. <i>Cancer Research</i> , <b>2009</b> , 69, 5194-201	10.1	84
110	Inhibition of thromboxane synthase induces lung cancer cell death via increasing the nuclear p27. <i>Experimental Cell Research</i> , <b>2009</b> , 315, 2974-81	4.2	15
109	Maintenance therapy in nonsmall-cell lung cancer: a new treatment paradigm. <i>Cancer</i> , <b>2009</b> , 115, 5143-54.4	23	

108	A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy. <i>Breast Cancer Research and Treatment</i> , <b>2009</b> , 113, 529-35	4.4	65
107	Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer. <i>Pathology and Oncology Research</i> , <b>2009</b> , 15, 651-8	2.6	87
106	Phase II study of irinotecan in combination with capecitabine as a first-line chemotherapy in Asian patients with inoperable hepatocellular carcinoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2009</b> , 5, 95-108	12.9	330
105	Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 2076-84	7.2	191
104	Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 5080-7	5.9	26
103	Third generation triplet cytotoxic chemotherapy in advanced non-small cell lung cancer: a systematic overview. <i>Lung Cancer</i> , <b>2009</b> , 64, 194-8	59.2	6253
102	Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. <i>New England Journal of Medicine</i> , <b>2009</b> , 361, 947-57	2.2	507
101	Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 605-11	21.7	21
100	First-line systemic treatment of advanced stage non-small-cell lung cancer in Asia: consensus statement from the Asian Oncology Summit 2009. <i>Lancet Oncology</i> , <b>2009</b> , 10, 1102-10	1.6	5
99	9007 Randomized, double-blind phase II/III study of first-line paclitaxel (P) plus carboplatin (C) in combination with vorinostat or placebo in patients with advanced non-small-cell lung cancer (NSCLC). <i>European Journal of Cancer, Supplement</i> , <b>2009</b> , 7, 507	2.2	
98	Predictors of treatment outcomes in early stage hepatocellular carcinoma (HCC) detected in a surveillance program. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 4584-4584	2.5	25
97	A small step towards personalized medicine for non-small cell lung cancer. <i>Discovery Medicine</i> , <b>2009</b> , 8, 227-31	3.7	25
96	Expression of cyclin D1 splice variants is differentially associated with outcome in non-small cell lung cancer patients. <i>Human Pathology</i> , <b>2008</b> , 39, 1792-801	9.9	94
95	Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signals. <i>Cancer Letters</i> , <b>2008</b> , 265, 307-17	40	1067
94	Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. <i>Lancet, The</i> , <b>2008</b> , 372, 1809-18	2.4	18
93	Transarterial ethanol ablation of hepatocellular carcinoma with lipiodol ethanol mixture: phase II study. <i>Journal of Vascular and Interventional Radiology</i> , <b>2008</b> , 19, 95-103	6.6	60
92	Genotype-specific genomic markers associated with primary hepatomas, based on complete genomic sequencing of hepatitis B virus. <i>Journal of Virology</i> , <b>2008</b> , 82, 3604-11	5.5	124
91	Quantitative analysis of circulating methylated DNA as a biomarker for hepatocellular carcinoma. <i>Clinical Chemistry</i> , <b>2008</b> , 54, 1528-36		

90	Haem oxygenase-1 plays a central role in NNK-mediated lung carcinogenesis. <i>European Respiratory Journal</i> , <b>2008</b> , 32, 911-23	13.6	29
89	High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 177-82	2.2	242
88	Systemic nonhormonal management of advanced prostate cancer and its likely impact on patients' survival and quality of life. <i>Anti-Cancer Drugs</i> , <b>2008</b> , 19, 645-53	2.4	7
87	A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells. <i>Investigational New Drugs</i> , <b>2008</b> , 26, 169-73	4.3	123
86	A comparison of three transarterial lipiodol-based formulations for hepatocellular carcinoma: in vivo biodistribution study in humans. <i>CardioVascular and Interventional Radiology</i> , <b>2008</b> , 31, 289-98	2.7	7
85	Familial occurrence of sequential B-cell lymphoma and myeloproliferative disease. <i>Annals of Hematology</i> , <b>2008</b> , 87, 931-2	3	
84	A phase II study of patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma and evaluation of plasma Epstein-Barr virus DNA as a biomarker of efficacy. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2008</b> , 62, 59-64	3.5	67
83	Increased inducible nitric oxide synthase in lung carcinoma of smokers. <i>Cancer</i> , <b>2008</b> , 112, 372-81	6.4	23
82	Evolutionary drug scheduling models with different toxicity metabolism in cancer chemotherapy. <i>Applied Soft Computing Journal</i> , <b>2008</b> , 8, 140-149	7.5	28
81	Complementary and Alternative Medicine: Believe it or not?. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2008</b> , 4, 123-124	1.9	1
80	Molecular and clinical subgroup analyses from a phase III trial comparing gefitinib with docetaxel in previously treated non-small cell lung cancer (INTEREST). <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 8001-8007	2.2	19
79	FAST-ACT: A phase II randomized double-blind trial of sequential erlotinib and chemotherapy as first-line treatment in patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC). <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 8031-8031	2.2	12
78	A double-blind placebo-controlled randomized study of Chinese herbal medicine as complementary therapy for reduction of chemotherapy-induced toxicity. <i>Annals of Oncology</i> , <b>2007</b> , 18, 768-74	10.3	66
77	MTP23-01: Salvage therapy for NSCLC. <i>Journal of Thoracic Oncology</i> , <b>2007</b> , 2, S289-S290	8.9	
76	Hepatitis B viral load predicts survival of HCC patients undergoing systemic chemotherapy. <i>Hepatology</i> , <b>2007</b> , 45, 1382-9	11.2	55
75	The epidermal growth factor receptor intron1 (CA) n microsatellite polymorphism is a potential predictor of treatment outcome in patients with advanced lung cancer treated with Gefitinib. <i>European Journal of Pharmacology</i> , <b>2007</b> , 570, 175-81	5.3	33
74	MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. <i>Science</i> , <b>2007</b> , 316, 1039-43	33.3	3705
73	KDR expression is associated with the stage and cigarette smoking of the patients with lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2007</b> , 133, 635-42	4.9	16



72	The Epic Story of Maximum Likelihood. <i>Statistical Science</i> , <b>2007</b> , 22, 598	2.4	63
71	PRS-02: Gefitinib (IRESSA) versus docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer pre-treated with platinum-based chemotherapy: a randomized, open-label Phase III study (INTEREST). <i>Journal of Thoracic Oncology</i> , <b>2007</b> , 2, S305-S306	8.9	57
70	Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China. <i>Journal of Thoracic Oncology</i> , <b>2007</b> , 2, 430-9	8.9	159
69	Sequential chemotherapy with combination irinotecan and cisplatin followed by docetaxel for treatment-naïve patients with advanced non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2007</b> , 2, 838-44	8.9	3
68	A memetic algorithm for multiple-drug cancer chemotherapy schedule optimization. <i>IEEE Transactions on Systems, Man, and Cybernetics</i> , <b>2007</b> , 37, 84-91		68
67	Evaluation of patupilone as monotherapy in patients with advanced hepatocellular carcinoma (HCC). <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 15055-15055	2.2	7
66	Fast Drug Scheduling Optimization Approach for Cancer Chemotherapy. <i>Lecture Notes in Computer Science</i> , <b>2007</b> , 1099-1107	0.9	0
65	Novel mutations and mutation pattern of epidermal growth factor receptor (EGFR) gene in Chinese patients with primary lung adenocarcinoma. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 7667-7667	2.2	
64	Possible correlation between SOCS1 methylation and EGFR exon 19 mutation but not exon 21 mutation in Chinese NSCLC patients. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 18113-18113	2.2	
63	A novel evolutionary drug scheduling model in cancer chemotherapy. <i>IEEE Transactions on Information Technology in Biomedicine</i> , <b>2006</b> , 10, 237-45		35
62	Apoptosis induced by troglitazone is both peroxisome proliferator-activated receptor-gamma- and ERK-dependent in human non-small lung cancer cells. <i>Journal of Cellular Physiology</i> , <b>2006</b> , 209, 428-38	7	64
61	Effects of patupilone (epothilone B; EPO906), a novel chemotherapeutic agent, in hepatocellular carcinoma: an in vitro study. <i>Oncology</i> , <b>2006</b> , 71, 292-6	3.6	19
60	Automating the drug scheduling with different toxicity clearance in cancer chemotherapy via evolutionary computation <b>2006</b> ,		3
59	Quality of life is predictive of survival in patients with unresectable hepatocellular carcinoma. <i>Annals of Oncology</i> , <b>2006</b> , 17, 1083-9	10.3	85
58	ASCO-ESMO consensus statement on quality cancer care. <i>Annals of Oncology</i> , <b>2006</b> , 17, 1063-4	10.3	31
57	Role of Non-Taxane-Containing Chemotherapy in Advanced Non-Small Cell Lung Cancer. <i>American Journal of Cancer</i> , <b>2006</b> , 5, 223-244		2
56	Increased thromboxane B(2) levels are associated with lipid peroxidation and Bcl-2 expression in human lung carcinoma. <i>Cancer Letters</i> , <b>2006</b> , 234, 193-8	9.9	20
55	Phase II Trial of Gemcitabine-Carboplatin-Paclitaxel as Neoadjuvant Chemotherapy for Operable Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , <b>2006</b> , 1, 135-140	8.9	7

54	Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 5878-85	12.9	295
53	Prevention of hepatitis B virus reactivation in patients with nasopharyngeal carcinoma with lamivudine. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2005</b> , 28, 379-84	2.7	51
52	Liver resection after irinotecan, 5-fluorouracil, and folinic acid for patients with unresectable colorectal liver metastases: a multicenter phase II study by the Cancer Therapeutic Research Group. <i>Medical Oncology</i> , <b>2005</b> , 22, 303-12	3.7	49
51	Knowledge, perceptions, and attitudes of Hong Kong Chinese women on screening mammography and early breast cancer management. <i>Breast Journal</i> , <b>2005</b> , 11, 52-6	1.2	48
50	Clear cell carcinoma of the lung revisited. <i>Journal of Thoracic and Cardiovascular Surgery</i> , <b>2005</b> , 130, 1198-9	3	7
49	Activation of peroxisome proliferator-activated receptor-gamma by troglitazone (TGZ) inhibits human lung cell growth. <i>Journal of Cellular Biochemistry</i> , <b>2005</b> , 96, 760-74	4.7	59
48	Correlation and prognostic significance of beta-galactoside alpha-2,6-sialyltransferase and serum monosialylated alpha-fetoprotein in hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , <b>2005</b> , 11, 6701-6	5.6	15
47	Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. <i>Journal of the National Cancer Institute</i> , <b>2005</b> , 97, 536-9	9.7	371
46	Phase II randomized study comparing the toxicity profile of gemcitabine plus cisplatin with gemcitabine plus oral etoposide in the treatment of advanced non-small cell lung cancer. <i>Oncology</i> , <b>2005</b> , 68, 485-92	3.6	14
45	An intensive surveillance program detected a high incidence of hepatocellular carcinoma among hepatitis B virus carriers with abnormal alpha-fetoprotein levels or abdominal ultrasonography results. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 8041-7	2.2	34
44	A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. <i>Journal of the National Cancer Institute</i> , <b>2005</b> , 97, 1532-8	9.7	490
43	Evolutionary Drug Scheduling Model for Cancer Chemotherapy. <i>Lecture Notes in Computer Science</i> , <b>2004</b> , 1126-1137	0.9	3
42	False-negative rate of abdominal sonography for detecting hepatocellular carcinoma in patients with hepatitis B and elevated serum alpha-fetoprotein levels. <i>American Journal of Roentgenology</i> , <b>2004</b> , 183, 453-8	5.4	11
41	Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. <i>Annals of Oncology</i> , <b>2004</b> , 15, 1661-6	10.3	132
40	Phase II study of neoadjuvant carboplatin and paclitaxel followed by radiotherapy and concurrent cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: therapeutic monitoring with plasma Epstein-Barr virus DNA. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 3053-60	2.2	103
39	Brain metastasis responding to gefitinib alone. <i>Oncology</i> , <b>2004</b> , 67, 174-8	3.6	32
38	A phase I safety and pharmacokinetic study of OGT 719 in patients with liver cancer. <i>Acta Oncologica</i> , <b>2004</b> , 43, 245-51	3.2	6
37	Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 927-34	2.2	226

36	Spectral karyotyping indicates complex rearrangements in lung adenocarcinoma of nonsmokers. <i>Cancer Genetics and Cytogenetics</i> , <b>2004</b> , 153, 57-9		9
35	Distinct patterns of genetic alterations in adenocarcinoma and squamous cell carcinoma of the lung. <i>European Journal of Cancer</i> , <b>2004</b> , 40, 1082-94	7.5	62
34	A new horizon of targeted therapy in management of lung cancer. <i>Chinese Journal of Lung Cancer</i> , <b>2004</b> , 7, 276-83	0.6	
33	Comprehensive proteomic profiling identifies serum proteomic signatures for detection of hepatocellular carcinoma and its subtypes. <i>Clinical Chemistry</i> , <b>2003</b> , 49, 752-60	5.5	208
32	Imatinib (STI-571) heals a gastrocutaneous fistula resulting from a malignant gastric stromal tumor. <i>Gastric Cancer</i> , <b>2003</b> , 6, 122-6	7.6	5
31	A prospective study of pre-treatment cell kinetics and clinical outcome in nasopharyngeal carcinoma. <i>Radiotherapy and Oncology</i> , <b>2003</b> , 69, 53-62	5.3	8
30	Genetic alterations of lung adenocarcinoma in relation to smoking and ethnicity. <i>Lung Cancer</i> , <b>2003</b> , 41, 91-9	5.9	18
29	Differential expression of inducible nitric oxide synthase and peroxisome proliferator-activated receptor gamma in non-small cell lung carcinoma. <i>European Journal of Cancer</i> , <b>2003</b> , 39, 1296-301	7.5	30
28	Unusual abdominal tumors: case 4. Multiple lymphomatous polyposis in mantle cell lymphoma. <i>Journal of Clinical Oncology</i> , <b>2003</b> , 21, 955-6	2.2	4
27	Adequate lymph node staging is fundamental to comparative study on resectable non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>2002</b> , 20, 2604-5; author reply 2605	2.2	1
26	Tumor p16M is a possible marker of advanced stage in non-small cell lung cancer. <i>Journal of Surgical Oncology</i> , <b>2002</b> , 79, 101-6	2.8	39
25	A Phase I-II study of sequential administration of topotecan and oral etoposide (topoisomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma. <i>Cancer</i> , <b>2002</b> , 95, 1511-9	6.4	24
24	Pretreatment factors predicting the development of postchemotherapy nausea and vomiting in Chinese breast cancer patients. <i>Supportive Care in Cancer</i> , <b>2002</b> , 10, 139-45	3.9	61
23	The effectiveness of progressive muscle relaxation training in managing chemotherapy-induced nausea and vomiting in Chinese breast cancer patients: a randomised controlled trial. <i>Supportive Care in Cancer</i> , <b>2002</b> , 10, 237-46	3.9	113
22	An analysis of the antiemetic protection of metoclopramide plus dexamethasone in Chinese patients receiving moderately high emetogenic chemotherapy. <i>European Journal of Cancer Care</i> , <b>2002</b> , 11, 108-13	2.4	
21	Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. <i>Journal of Clinical Oncology</i> , <b>2002</b> , 20, 2038-44	2.2	382
20	Phase II study of docetaxel and epirubicin in Chinese patients with metastatic breast cancer. <i>Anti-Cancer Drugs</i> , <b>2002</b> , 13, 655-62	2.4	9
19	Pharmacokinetic study of intralesional cisplatin for the treatment of hepatocellular carcinoma. <i>Cancer</i> , <b>2001</b> , 91, 2369-2377	6.4	20

18	Application of classification tree and neural network algorithms to the identification of serological liver marker profiles for the diagnosis of hepatocellular carcinoma. <i>Oncology</i> , <b>2001</b> , 61, 275-83	3.6	29
17	Hepatocellular carcinoma and lymphoma--two hepatitis B virus-related malignant diseases. <i>Lancet Oncology, The</i> , <b>2001</b> , 2, 543	21.7	3
16	The cost of palliative care for hepatocellular carcinoma in Hong Kong. <i>Pharmacoeconomics</i> , <b>2001</b> , 19, 947-53	4.4	21
15	Lack of expression for the suppressor PML in human small cell lung carcinoma. <i>International Journal of Cancer</i> , <b>2000</b> , 85, 599-605	7.5	40
14	Sonographic findings in masseter-muscle metastases. <i>Journal of Clinical Ultrasound</i> , <b>2000</b> , 28, 299-302	1	12
13	A phase II study of gemcitabine plus oral etoposide in the treatment of patients with advanced nonsmall cell lung carcinoma. <i>Cancer</i> , <b>2000</b> , 89, 543-550	6.4	17
12	Hemorrhagic pyelitis, ureteritis, and cystitis secondary to cyclophosphamide: case report and review of the literature. <i>Gynecologic Oncology</i> , <b>2000</b> , 76, 223-5	4.9	23
11	Frequent c-myc and Int-2 overrepresentations in nasopharyngeal carcinoma. <i>Human Pathology</i> , <b>2000</b> , 31, 169-78	3.7	58
10	Clinical outcomes of post-operative locoregional radiotherapy in pre-menopausal and post-menopausal Chinese women with breast cancer. <i>Radiotherapy and Oncology</i> , <b>2000</b> , 54, 201-8	5.3	4
9	A multi-centre randomized phase II study of nolatrexed versus doxorubicin in treatment of Chinese patients with advanced hepatocellular carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , <b>1999</b> , 44, 307-11	3.5	42
8	Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy. <i>Journal of Medical Virology</i> , <b>1999</b> , 59, 263-9	19.7	68
7	Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. <i>Lancet, The</i> , <b>1999</b> , 353, 797-801	40	373
6	Application of the international prognostic index in a study of Chinese patients with non-Hodgkin's lymphoma and a high incidence of primary extranodal lymphoma. <i>Cancer</i> , <b>1998</b> , 82, 2439-48	6.4	18
5	Multimodality treatment of primary lymphoepithelioma-like carcinoma of the lung. <i>Cancer</i> , <b>1998</b> , 83, 925-9	6.4	46
4	Phase II study of Temodal in the treatment of patients with advanced nasopharyngeal carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , <b>1998</b> , 42, 247-9	3.5	10
3	A phase II study of combination paclitaxel and carboplatin in advanced nasopharyngeal carcinoma. <i>European Journal of Cancer</i> , <b>1998</b> , 34, 2027-31	7.5	88
2	Autologous bone marrow transplantation versus MACOP-B in B-cell lymphoma. <i>New England Journal of Medicine</i> , <b>1997</b> , 337, 711; author reply 711-2	59.2	1
1	Optimal Control of a Cancer Chemotherapy Problem with Different Toxic Elimination Processes		1

